PMID- 19963100
OWN - NLM
STAT- MEDLINE
DCOM- 20100121
LR  - 20191210
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 36 Suppl 3
DP  - 2009 Dec
TI  - Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
PG  - S46-58
LID - 10.1053/j.seminoncol.2009.10.010 [doi]
AB  - Activation of mammalian target of rapamycin (mTOR) signaling occurs in a wide 
      variety of human tumors and can lead to increased susceptibility to mTOR 
      inhibitors. Temsirolimus, a novel analog of rapamycin, has shown promising 
      preclinical and early clinical anti-tumor activity in various solid and 
      hematologic tumor types, either alone or in combination with chemotherapy or 
      other targeted agents. Randomized phase III trials have already demonstrated 
      significant clinical benefits of treatment with single-agent temsirolimus in 
      advanced renal cell carcinoma and relapsed and/or refractory mantle cell 
      lymphoma. Other malignancies studied in the phase I and II trial settings include 
      glioblastoma, breast cancer, endometrial cancer, non-Hodgkin lymphomas, and 
      multiple myeloma. This article reviews a comprehensive collection of the clinical 
      trial results reported to date for temsirolimus in various solid and hematologic 
      malignancies, as well as current strategies being tested in ongoing trials. The 
      findings with temsirolimus in multiple tumors provide a valuable framework for 
      future development of temsirolimus and other mTOR inhibitors.
FAU - Dancey, Janet E
AU  - Dancey JE
AD  - The Ontario Institute for Cancer Research, MaRS Centre, 101 College Street, 
      Toronto, ON, Canada. janet.dancey@oicr.on.ca
FAU - Curiel, Rafael
AU  - Curiel R
FAU - Purvis, Joseph
AU  - Purvis J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antineoplastic Agents)
RN  - 624KN6GM2T (temsirolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Hematologic Neoplasms/drug therapy
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Sirolimus/*analogs & derivatives/therapeutic use
RF  - 91
EDAT- 2010/01/09 06:00
MHDA- 2010/01/22 06:00
CRDT- 2009/12/08 06:00
PHST- 2009/12/08 06:00 [entrez]
PHST- 2010/01/09 06:00 [pubmed]
PHST- 2010/01/22 06:00 [medline]
AID - S0093-7754(09)00192-4 [pii]
AID - 10.1053/j.seminoncol.2009.10.010 [doi]
PST - ppublish
SO  - Semin Oncol. 2009 Dec;36 Suppl 3:S46-58. doi: 10.1053/j.seminoncol.2009.10.010.